Ainos (AIMD) Competitors $0.43 0.00 (-0.70%) (As of 11:13 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends AIMD vs. CVKD, CMMB, PULM, TPST, COCP, ACXP, XCUR, IBIO, GLYC, and PIRSShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Cadrenal Therapeutics (CVKD), Chemomab Therapeutics (CMMB), Pulmatrix (PULM), Tempest Therapeutics (TPST), Cocrystal Pharma (COCP), Acurx Pharmaceuticals (ACXP), Exicure (XCUR), iBio (IBIO), GlycoMimetics (GLYC), and Pieris Pharmaceuticals (PIRS). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Cadrenal Therapeutics Chemomab Therapeutics Pulmatrix Tempest Therapeutics Cocrystal Pharma Acurx Pharmaceuticals Exicure iBio GlycoMimetics Pieris Pharmaceuticals Cadrenal Therapeutics (NASDAQ:CVKD) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking. Do analysts rate CVKD or AIMD? Cadrenal Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 28.02%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, CVKD or AIMD? Cadrenal Therapeutics has higher earnings, but lower revenue than Ainos. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$8.36M-$6.68-2.11Ainos$120K49.25-$13.77MN/AN/A Does the MarketBeat Community believe in CVKD or AIMD? Cadrenal Therapeutics received 6 more outperform votes than Ainos when rated by MarketBeat users. CompanyUnderperformOutperformCadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesAinosN/AN/A Do insiders and institutionals have more ownership in CVKD or AIMD? 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CVKD or AIMD more profitable? Cadrenal Therapeutics has a net margin of 0.00% compared to Ainos' net margin of -15,348.14%. Ainos' return on equity of -75.16% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -142.95% -118.40% Ainos -15,348.14%-75.16%-50.22% Which has more risk & volatility, CVKD or AIMD? Cadrenal Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Ainos has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Does the media favor CVKD or AIMD? In the previous week, Cadrenal Therapeutics had 3 more articles in the media than Ainos. MarketBeat recorded 3 mentions for Cadrenal Therapeutics and 0 mentions for Ainos. Ainos' average media sentiment score of 0.49 beat Cadrenal Therapeutics' score of 0.41 indicating that Ainos is being referred to more favorably in the news media. Company Overall Sentiment Cadrenal Therapeutics Neutral Ainos Neutral SummaryCadrenal Therapeutics beats Ainos on 10 of the 14 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.91M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E RatioN/A4.9791.2813.60Price / Sales49.25371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book0.3310.306.906.33Net Income-$13.77M$153.61M$118.83M$225.93M7 Day Performance-11.25%-1.73%-1.92%-0.96%1 Month Performance-24.96%-7.26%-3.75%1.06%1 Year Performance-86.59%31.10%31.37%26.59% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos0.6806 of 5 stars$0.43-0.7%N/A-86.2%$5.91M$120,000.000.0046Gap DownCVKDCadrenal Therapeutics1.683 of 5 stars$14.06-3.0%$18.00+28.0%N/A$23.34MN/A0.004Gap UpCMMBChemomab Therapeutics2.8753 of 5 stars$1.58-3.7%$7.33+364.1%+228.0%$22.69MN/A0.0020PULMPulmatrix0.26 of 5 stars$6.21+10.5%N/A+210.5%$22.67M$7.30M-2.2820Analyst ForecastGap UpTPSTTempest Therapeutics2.2548 of 5 stars$0.89-0.7%$20.00+2,141.4%-76.2%$22.50MN/A-0.5920Analyst RevisionCOCPCocrystal Pharma3.0393 of 5 stars$2.20+6.8%$7.00+218.2%+25.6%$22.37MN/A-1.1710Gap UpACXPAcurx Pharmaceuticals2.3848 of 5 stars$1.30-6.5%$12.00+823.0%-61.6%$21.96MN/A0.003Short Interest ↓Analyst RevisionNews CoverageGap UpXCURExicure1.8025 of 5 stars$9.56-14.6%N/A+1,914.4%$20.75M$28.83M-4.9550News CoverageGap DownIBIOiBio1.3721 of 5 stars$2.26+3.2%$4.30+90.3%N/A$20.68M$220,000.000.00100Positive NewsGap UpGLYCGlycoMimetics3.442 of 5 stars$0.32-4.0%$10.00+3,057.6%-78.4%$20.42M$10,000.000.0050Gap DownPIRSPieris Pharmaceuticals1.6293 of 5 stars$15.39-3.9%N/A-10.4%$20.32M$42.81M-1.32140Analyst UpgradeNews Coverage Related Companies and Tools Related Companies CVKD Competitors CMMB Competitors PULM Competitors TPST Competitors COCP Competitors ACXP Competitors XCUR Competitors IBIO Competitors GLYC Competitors PIRS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AIMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
